Trastuzumab reduces tumor growth and survival by binding to the ECD subdomain IV of HER2, blocking downstream signaling pathways, and inducing antibody-dependent cellular cytotoxicity (ADCC) [21]. The gene discussed is ERBB2; the disease is neoplasm.